Stock MOREPENLAB MOREPEN LABORATORIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Morepen Laboratories Limited Stock

Equities

MOREPENLAB

INE083A01026

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:47 2024-04-18 am EDT 		5-day change 1st Jan Change
46.57 INR +1.00% Intraday chart for Morepen Laboratories Limited +1.02% -4.04%
Mar. 30 Morepen Laboratories Limited Announces Resignation of Lalit Kumar Baregama, Chief Growth Officer CI
Mar. 01 Morepen Laboratories Limited Announces the Promotion of Amita Sharma to Chief Operating Officer -API CI

Financials

Sales 2022 15.56B 186M Sales 2023 14.22B 170M Capitalization 13.13B 157M
Net income 2022 1.02B 12.18M Net income 2023 387M 4.63M EV / Sales 2022 1.2 x
Net Debt 2022 1.17B 14.06M Net Debt 2023 34.98M 419K EV / Sales 2023 0.93 x
P/E ratio 2022
18.7 x
P/E ratio 2023
33.4 x
Employees 1,649
Yield 2022 *
-
Yield 2023
-
Free-Float 52.17%
More Fundamentals * Assessed data

Chart Morepen Laboratories Limited

Dynamic Chart

Latest news about Morepen Laboratories Limited

Morepen Laboratories Limited Announces Resignation of Lalit Kumar Baregama, Chief Growth Officer CI
Morepen Laboratories Limited Announces the Promotion of Amita Sharma to Chief Operating Officer -API CI
Morepen Laboratories Limited Approves the Appointment of Vikas Sharma, Talent Acquisition & HRBP, Functional Head CI
Morepen Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Morepen Laboratories Limited Announces Resignation of Rolli Saxena, General Manager - HR, Being A Functional Head and Senior Management Personnel CI
Morepen Laboratories Limited Appoints Shantanu Tuli as President -Strategy and Brand Identity, Effective from December 1, 2023 CI
Morepen Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Morepen Laboratories to Transfer Formulation Distribution and Marketing Business to Subsidiary MT
Morepen Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Morepen Laboratories' Net Profit Drops in Fiscal Q4 MT
Morepen Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
US FDA Clears Morepen Laboratories' Baddi, India MT
Morepen Laboratories Forms Wholly-Owned Subsidiary MT
Morepen Laboratories Limited Announces Incorporation of Wholly Owned Subsidiary CI
Morepen Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
More news

Press releases Morepen Laboratories Limited

Morepen Laboratories : Dr. Morepen Partners with OptiBiotix to Deliver Safe, ScienceBacked Weight Management Solution to India PU
Morepen Laboratories : Investors presentation - Q1' FY 2023-24 PU
Morepen Laboratories : Transcript of EGM dated March 05, 2022  Audited Financial results for the quarter and financial year ended March 31, 2022  Unaudited financial results for the quarter and nine months ended December 31, 2021  Unaudited Financial results for the quarter and half year ended September 30, 2021  Unaudited Financial results for the quarter ended June 30, 2021 PU
Morepen Laboratories : Investor Presentation Q1' FY 2022-23 PU
Morepen Laboratories : Unaudited Financial results for the quarter ended June 30, 2022 PU
More press releases

Quotes and Performance

1 day+1.00%
1 week+1.02%
Current month+10.72%
1 month+10.67%
3 months-0.85%
6 months+30.85%
Current year-4.04%
More quotes

Highs and lows

1 week
43.15
Extreme 43.15
48.01
1 month
40.23
Extreme 40.23
49.15
Current year
38.56
Extreme 38.56
56.35
1 year
25.34
Extreme 25.34
56.35
3 years
23.65
Extreme 23.65
75.00
5 years
7.21
Extreme 7.21
75.00
10 years
3.85
Extreme 3.85
75.00
More quotes

Managers and Directors - Morepen Laboratories Limited

Managers TitleAgeSince
Sushil Suri CEO
 Chief Executive Officer 60 92-01-31
Ajay Kumar Sharma DFI
 Director of Finance/CFO 57 02-04-02
Vipul Kumar Srivastava CMP
 Compliance Officer 38 18-11-11
Members of the board TitleAgeSince
Sanjay Suri BRD
 Director/Board Member 55 19-08-12
Sushil Suri CEO
 Chief Executive Officer 60 92-01-31
Sukhcharan Singh BRD
 Director/Board Member 81 05-06-14
More insiders

ETFs positioned on Morepen Laboratories Limited

Name Weight AuM 1st Jan change Investor Rating
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.00% 117 M€ -0.62% -
More ETFs positioned on Morepen Laboratories Limited

Quotes

Date Price Change Volume
24-04-18 46.57 +1.00% 363 332
24-04-16 46.11 +3.85% 508,819
24-04-15 44.4 -3.69% 677,290
24-04-12 46.1 -0.65% 338,389
24-04-10 46.4 -1.15% 373,806

Delayed Quote Bombay S.E., April 18, 2024 at 06:00 am EDT

More quotes

Company Profile

Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Febuxostat, Montelukast (Oral), Montelukast (Chewable), among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen 49W Room Air Purifier with HEPA Filter, Dr. Morepen VP06 Breathe Free Vaporizer, Dr. Morepen CN06 Compressor Nebulizer and Dr. Morepen ST03 Dual Head Stethoscope, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Sector
Pharmaceuticals
Calendar
2024-05-01 - Q4 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

1st Jan change Capi.
MOREPEN LABORATORIES LIMITED Stock Morepen Laboratories Limited
-4.04% 282M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+28.66% 676B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+23.58% 554B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.65% 349B
MERCK & CO., INC. Stock Merck & Co., Inc.
+14.50% 318B
ABBVIE INC. Stock AbbVie Inc.
+7.09% 291B
ASTRAZENECA PLC Stock AstraZeneca PLC
+2.96% 210B
NOVARTIS AG Stock Novartis AG
-0.41% 204B
ROCHE HOLDING AG Stock Roche Holding AG
-10.02% 194B
PFIZER, INC. Stock Pfizer, Inc.
-12.19% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MOREPENLAB Stock